MedTrace Logo

The Safety and Efficacy Study of RiaGev in Healthy Adults

NCT04483011 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-11-25

Study results available
· View outcomes & findings →

Summary

This current randomized, double-blind, comparator-controlled, cross over study investigates the efficacy and safety of RiaGev™ via evaluation of NAD+, ATP, glucose, insulin, glutathione, and cortisol levels in healthy adults of ages 36-65.

Conditions

  • Metabolic Syndrome
  • Premature Aging

Interventions

DIETARY_SUPPLEMENT

RiaGev

Dietary supplementation

Sponsors & Collaborators

  • KGK Science Inc.

    collaborator INDUSTRY

  • University of Washington

    collaborator OTHER

  • Bioenergy Life Science, Inc.

    lead INDUSTRY

Principal Investigators

  • Malkanthi Evans, Ph.D · KGK Science Inc.

  • Trisha Shamp, PA-C, Ph.D · Prism Research, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
36 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-25
Primary Completion
2020-07-30
Completion
2020-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04483011 on ClinicalTrials.gov